The most recent update to NIH COVID-19 Treatment Guidelines incorporates RCT data on use of antivirals, immunomodulators, and colchicine as treatment for SARS-CoV-2 infection.
The National Institutes of Health (NIH) on July 8, 2021, published a revised version of the "living" Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
Updates are made regularly based on availability for review by the COVID-19 Treatment Guidelines Panel (the Panel) of new data related to assessment and general and therapeutic management of persons at risk for or diagnosed as having infection with SARS-CoV-2.
Following are highlights of major changes made to the guidelines within the last month.
Nitazoxanide, New Section. The Panel recommends against the use of nitazoxanide for the treatment of COVID-19, except in a clinical trial.
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Inhibitors, New Section. The Panel has determined evidence is insufficient to recommend either for or against the use of GM-CSF inhibitors for treatment of hospitalized patients with COVID-19.
Baricitinib in Therapeutic Management of Hospitalized Patients with COVID-19, Key Update. Based on results from the COV-BARRIER trial, the Panel recommends against the combined use of baricitinib and tocilizumab.
Chloroquine or Hydroxychloroquine and/or Azithromycin, Key Update. Includes revised recommendation for use of these agents in nonhospitalized patients and adds a recommendation on azithromycin monotherapy. The Panel recommends against use of chloroquine or hydroxychloroquine and/or azithromycin to treat COVID-19 in hospitalized and nonhospitalized patients
Colchicine, Key Update. A large, unpublished RCT (RECOVERY) showed no difference in 28-day all-cause mortality between patients who received colchicine and those who received usual care. The Panel now recommends against the use of colchicine to treat hospitalized patients with COVID-19.
Special Considerations in Pregnancy, Key Update. In general, the therapeutic management of
pregnant patients with COVID-19 should be the same as for nonpregnant patients. The Panel recommends against withholding treatment for COVID-19 and SARS-CoV-2 vaccination from pregnant or lactating individuals because of theoretical safety concerns.
Review key update details and the full guideline here: Coronavirus Disease 2019 (COVID-19) Treatment Guidelines